Suven Pharmaceuticals Share price, Balance Sheet, Annual report and Quarterly Results for company analysis 

Welcome to our stock analysis page for Suven Pharmaceuticals Ltd., a leading player in the Indian Pharmaceutical Industry. As an Indian long-term stock investor, you are likely always on the lookout for valuable investment opportunities with the potential for growth over time. Ticker provides a comprehensive guide to Suven Pharmaceuticals Ltd.'s stock analysis, offering insights into its share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

In addition to providing an in-depth analysis of these key strategies, we offer pre-built screening tools that help investors track the performance of the stock. Ticker also provides downloadable annual reports and quarterly results, allowing you to stay up-to-date with the company’s performance.

Through assessing the balance sheet, quarterly results, and profit and loss, Ticker’s premium features allow for fair value calculation using tools - DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. With these tools, you gain a deeper understanding of the company's financial position, enabling you to make better investment decisions.

Suven Pharmaceuticals Ltd Share Price 

The share price of Suven Pharmaceuticals Ltd. is an important metric for assessing the company's market sentiment and investor perception. Ticker provides the latest share price information and pre-built screening tools to help investors track the stock's performance. By keeping a close eye on market trends, investors can make more informed buying, selling, or holding decisions for Suven Pharmaceuticals Ltd.

Suven Pharmaceuticals Ltd Balance Sheet 

Suven Pharmaceuticals Ltd.'s balance sheet offers a window into the company's financial position by providing valuable information on its assets, liabilities, and shareholders’ equity. Through Ticker's premium tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, investors can make fair value calculations for the company. By analyzing the balance sheet, investors can gain a better understanding of the company's relative financial health and stability, providing vital information to guide their investment strategy.

Suven Pharmaceuticals Ltd Annual Report 

The Suven Pharmaceuticals Ltd. annual report gives an in-depth analysis of the company's performance, strategy, and future plans, making it essential reading for investors. Ticker provides annual reports as downloadable files for investors to read and analyze. By studying the annual report, investors can understand the company's business prospects, assess its ability to pay dividends, and make well-informed investment decisions.

Suven Pharmaceuticals Ltd Dividend 

For investors seeking income from their investments, tracking a company's dividend history and making informed decisions accordingly is an essential step. Ticker provides information on Suven Pharmaceuticals Ltd.'s dividend payments and history. By studying dividend payouts, investors can understand the company's fiscal health and predict its ability to pay out future dividends.

Suven Pharmaceuticals Ltd Quarterly Result 

Assessing the quarterly results of Suven Pharmaceuticals Ltd. in terms of revenue, expenses, and profits is essential for long-term investors to gauge the financial performance of the company. As such, Ticker offers downloadable quarterly reports that provide an in-depth analysis of the company's financial position. By understanding the trends and developments highlighted in these reports, investors can make more informed decisions about buying, holding or selling the stock.

Suven Pharmaceuticals Ltd Stock Price 

Tracking the stock price of Suven Pharmaceuticals Ltd. is one of the crucial steps investors must take to assess how the market perceives the company's potential for growth and future prospects. Ticker provides real-time stock price information. Tracking historical stock trends through the website's pre-built screening tools is an excellent way to gain a deeper understanding of market sentiment and assist in making better-informed investment decisions.

Suven Pharmaceuticals Ltd Price Chart 

For technical analysis purposes, visual representation of the company's stock price movements is crucial. As such, Ticker offers price charts of Suven Pharmaceuticals Ltd. By studying historical trends and patterns, investors can develop trading strategies. Moreover, using tools like DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis can reinforce their investment approach.

Suven Pharmaceuticals Ltd News 

Being well-informed on the latest news and developments about Suven Pharmaceuticals Ltd. is important for investors looking to make strategic investment decisions. Ticker provides a dedicated news section, covering the latest updates and announcements related to the company. By staying up-to-date with the latest company news, investors can change their investment strategy based on new information and market trends.

Suven Pharmaceuticals Ltd ConcCall Transcripts 

Concall transcripts of Suven Pharmaceuticals Ltd. offer valuable insights into the company's management discussions, strategy, and performance. Ticker offers downloadable concall transcripts. By analyzing the transcripts, investors can keep abreast of key developments and changes, giving them the edge to make informed investment decisions.

Suven Pharmaceuticals Ltd Investor Presentations 

Studying the investor presentations of Suven Pharmaceuticals Ltd. is a smart way to understand the company’s strategy, business model, and long-term growth plans. Ticker offers downloadable investor presentations in a comprehensive format for investors, allowing them to gain a better perspective on the company's performance plans. With our fair value calculation tools, including DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, investors can gauge the long-term growth potential of Suven Pharmaceuticals Ltd.

Suven Pharmaceuticals Ltd Promoters 

Promoters are key figures in Suven Pharmaceuticals Ltd.’s success, and understanding them is as critical as balancing the balance sheet. By studying the promoters' shareholding pattern and background, investors can form a better understanding of the management team's motivations, competence, and credibility. Ticker provides comprehensive information on Suven Pharmaceuticals Ltd.'s promoters to assist investors in their research.

Suven Pharmaceuticals Ltd Shareholders 

Knowing and analyzing the shareholding pattern of Suven Pharmaceuticals Ltd. is helpful in determining investor sentiment. Ticker provides information on the company's major shareholders and institutional investors. Understanding investors' interest levels can better assist and inform an individual's investment strategy.

Suven Pharmaceuticals Ltd ROCE

Return on Capital Employed (ROCE) is a key financial ratio that provides insight into the efficiency and profitability of Suven Pharmaceuticals Ltd's capital investments. This ratio helps investors understand how well the company is utilizing its capital to generate profits. You can find the ROCE data for Suven Pharmaceuticals Ltd in the financials table or the ratio section on this page.

Suven Pharmaceuticals Ltd EBITDA

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a metric that reveals Suven Pharmaceuticals Ltd's operating performance and profitability before accounting for non-operating expenses. By analyzing EBITDA, investors can gauge the company's core operational earnings. To access Suven Pharmaceuticals Ltd's EBITDA data, refer to the financials table or the ratio section above.

Suven Pharmaceuticals Ltd DPS

Dividends Per Share (DPS) signifies the portion of Suven Pharmaceuticals Ltd's profits distributed to shareholders per outstanding share. This metric is crucial for income investors seeking steady dividend income. You can easily locate Suven Pharmaceuticals Ltd's DPS information in the financials table or the ratio section on this page.

Suven Pharmaceuticals Ltd EPS

Earnings Per Share (EPS) indicates the portion of Suven Pharmaceuticals Ltd's profit allocated to each outstanding share of its common stock. Analyzing EPS helps investors evaluate the company's profitability on a per-share basis. To access Suven Pharmaceuticals Ltd's EPS data, navigate to the financials table or the ratio section provided above. 

Suven Pharmaceuticals' Equity and Liabilities Evolution

Over the years, Suven Pharmaceuticals has seen significant changes in its equity and liabilities structure, reflecting the company's evolution. The share capital has remained stable at Rs. 25.46 Cr. from March 2021 onwards, indicating no further dilution or capital raise through equity. However, a noticeable increase in total reserves, growing from Rs. 770.10 Cr. in Mar 2020 to Rs. 2,030.44 Cr. by Mar 2024, showcases the company's strong profit retention and reinvestment strategy. The reduction of borrowings to zero by Mar 2024 from Rs. 91.25 Cr. in Mar 2020 highlights the company's focus on reducing debt and improving its financial health.

Suven Pharmaceuticals' Asset Growth

Suven Pharmaceuticals' asset base has expanded significantly, with total assets increasing from Rs. 1,230.35 Cr. in Mar 2020 to Rs. 2,338.86 Cr. by Mar 2024. This growth is backed by a substantial increase in current assets, which rose to Rs. 1,307.69 Cr. by Mar 2024, indicating enhanced operational efficiency and working capital management. The consistent investment in Net Block and Capital WIP illustrates the company's commitment to growth and capacity expansion.

Expansion and Reduction in Suven Pharmaceuticals' Liabilities

A notable reduction in borrowings and a well-managed liability structure demonstrate Suven Pharmaceuticals' prudent financial management. The company's liabilities have been strategically structured, with a significant paydown in borrowings and an appropriate handling of current liabilities, which decreased to Rs. 203.58 Cr. by Mar 2024. This strategic financial maneuvering supports Suven Pharmaceuticals' growth trajectory while ensuring financial stability.

This data is an analysis for the Standalone Balance sheet of the company.

Engaging with Suven Pharmaceuticals' financial health could offer insights into potential market movements, beneficial for investors looking into the pharma sector or tracking NSE and BSE indices for informed investment decisions. 

Suven Life Sciences Reserves Growth

Suven Life Sciences has shown a robust increase in its total reserves, escalating from Rs. 374.95 Cr in March 2020 to Rs. 823.57 Cr by March 2024. This growth trajectory underscores the company's reinforced financial foundation and capacity for re-investment in its operations or ventures.

Suven Life Sciences Debt Analysis

Remarkably, Suven Life Sciences has minimized its borrowings effectively to zero by March 2022 and maintained this stance through March 2024. Originally standing at Rs. 1.08 Cr in March 2020, this strategic reduction in debt highlights the company's initiative towards achieving a debt-free status.

Suven Life Sciences Asset Expansion

The asset profile of Suven Life Sciences has observed substantial changes, with total assets increasing from Rs. 503.28 Cr in March 2020 to Rs. 851.48 Cr in March 2024. Notably, the investments have surged impressively from Rs. 241.81 Cr to Rs. 577.11 Cr, indicating a strategic focus on capital growth and value enhancement over the years.

Suven Life Sciences Current Liabilities and Liquidity Position

Suven Life Sciences shows a significant decrease in current liabilities, from Rs. 103.53 Cr in March 2020 to an astounding low of Rs. 4.76 Cr by March 2024. This remarkable reduction signifies improved liquidity and better financial health.

This analysis has been provided based on the Standalone Balance Sheet of Suven Life Sciences, reflecting the company's financial position over the years.

Suven Life Sciences' journey may interest investors focusing on sectors showing strong resilience and growth prospects, paralleling keen market observations across NSE BSE indices, highlighting the significance of strategic financial management within the bio-pharmaceutical industry.